☆ 4.5 Article

Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunich(LMU) Molecular Tumor Board

TARGETED ONCOLOGY (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

Lessons learned: the first consecutive 1000 patients of the CCCMunichLMU Molecular Tumor Board

Kathrin Heinrich et al.

Summary: This study retrospectively analyzed the first 1000 cases of the University of Munich Molecular Tumor Board (MTB) precision oncology program. The results showed that patients with breast and biliary tract cancers were more likely to have actionable genetic variants. However, only 17% of patients implemented the treatment recommendations from the tumor board, highlighting the importance of meticulous follow-up and broad access to innovative therapies for these patients.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2023)

添加到收藏夹

Article Oncology

Serum biomarker panel diagnostics in pancreatic ductal adenocarcinoma: the clinical utility of soluble interleukins, IFN-γ, TNF-α and PD-1/PD-L1 in comparison to established serum tumor markers

Klara Dorman et al.

Summary: Novel biomarkers have been identified in pancreatic ductal adenocarcinoma (PDAC) to predict the treatment outcome and guide therapeutic strategies. IL-10 and CYFRA 21-1 levels have been found to be associated with the survival of PDAC patients. IL-10 levels may have independent prognostic value in locally advanced PDAC, whereas CYFRA 21-1 levels are prognostic after PDAC surgery.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2023)

添加到收藏夹

Review Pharmacology & Pharmacy

Novel systemic treatment approaches for metastatic pancreatic cancer

Klara Dorman et al.

Summary: With a 5-year overall survival rate of 10%, more effective therapies are needed for metastatic PDAC. Emerging drugs in clinical development, including cellular therapies, are being investigated to overcome the challenges of the immunosuppressive tumor microenvironment, poor vascularization, and dense tumor stroma typical for PDAC. Exciting clinical trials are ongoing, with a focus on targeted treatments and personalized therapy plans for PDAC patients.

EXPERT OPINION ON INVESTIGATIONAL DRUGS (2022)

添加到收藏夹

Article Medicine, Research & Experimental

Enrollment of female participants in United States drug and device phase 1-3 clinical trials between 2016 and 2019

Alexandra Z. Sosinsky et al.

Summary: Historically, there has been an underrepresentation of females in clinical trials. This study assessed the participation of females in recent clinical trials and found that they are still underrepresented compared to their proportion in the disease population. Adequate inclusion of females in clinical trials is critical for understanding treatment responses and toxicities specific to women.

CONTEMPORARY CLINICAL TRIALS (2022)

添加到收藏夹

Article Medicine, General & Internal

Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer

Rom Leidner et al.

Summary: The patient with progressive metastatic pancreatic cancer showed regression of visceral metastases after receiving infusion of genetically engineered autologous T cells targeting mutant KRAS G12D, with an overall partial response of 72% according to the Response Evaluation Criteria in Solid Tumors, version 1.1. The response was ongoing at 6 months, and the engineered T cells accounted for more than 2% of all circulating peripheral-blood T cells.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

S3 Guideline on exocrine Pancreatic Cancer Short Version 2.0-December 2021, AWMF- Register Number: 032/010OL

Thomas Seufferlein et al.

ZEITSCHRIFT FUR GASTROENTEROLOGIE (2022)

添加到收藏夹

Article Oncology

Cancer Statistics, 2021

Rebecca L. Siegel et al.

Summary: Every year, the American Cancer Society projects the numbers of new cancer cases and deaths in the United States, with the latest data showing a significant decline in lung cancer mortality, while prostate cancer mortality has plateaued and breast and colorectal cancer mortality have slowed. Improvements in treatment have accelerated progress against lung cancer, leading to a record drop in overall cancer mortality.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

添加到收藏夹

Article Oncology

Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 2013 and 2017

Ding Ding et al.

Summary: Genomic profiling can guide personalized treatment for pancreatic ductal adenocarcinoma patients, but the percentage of patients receiving targeted therapy is currently low. The main challenges lie in ordering testing early in the disease course and the limited evidence for targeted approaches in these patients.

CANCER LETTERS (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

Molecular Alterations in Pancreatic Cancer: Transfer to the Clinic

Yolanda Rodriguez Gil et al.

Summary: Pancreatic ductal adenocarcinoma is the most common cancer of the exocrine pancreas, but has benefited the least from clinical progress in the last three decades. Despite advances in understanding the molecular alterations and subtypes of the tumor, effective treatment options remain limited. More research is needed to identify new drugs and improve survival rates for PDA patients.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

Small molecules in targeted cancer therapy: advances, challenges, and future perspectives

Lei Zhong et al.

Summary: Targeted therapeutic drugs have become mainstream cancer treatments due to their advantages in efficacy and safety, but still face challenges such as low response rate and drug resistance. A comprehensive review was conducted on small-molecule targeted anti-cancer drugs to promote their development, discussing current challenges and providing insights and perspectives for future research and development.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)

添加到收藏夹

Article Oncology

Trametinib and Hydroxychloroquine (HCQ) Combination Treatment in KRAS-Mutated Advanced Pancreatic Adenocarcinoma: Detailed Description of Two Cases

Camila B. Xavier et al.

Summary: Cytotoxic chemotherapy has been the main treatment for metastatic pancreatic adenocarcinoma, but resistance is common due to KRAS mutations in 90% of cases. One alternative approach is using a MEK inhibitor along with an autophagy inhibitor, which has shown promise in overcoming resistance. Real-life data on KRAS-mutated PDAC patients treated with this regimen align with preclinical data, indicating clinical benefits.

JOURNAL OF GASTROINTESTINAL CANCER (2021)

添加到收藏夹

Review Pharmacology & Pharmacy

New Treatment Strategies for Metastatic Pancreatic Ductal Adenocarcinoma

Ritu Raj Singh et al.

DRUGS (2020)

添加到收藏夹

Review Oncology

Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group

F. Mosele et al.

ANNALS OF ONCOLOGY (2020)

添加到收藏夹

Article Medicine, Research & Experimental

Therapeutic management of neuro-oncologic patients - potential relevance of CSF liquid biopsy

Louisa von Baumgarten et al.

THERANOSTICS (2020)

添加到收藏夹

Article Oncology

Evolving Landscape of Molecular Prescreening Strategies for Oncology Early Clinical Trials

Rodrigo Dienstmann et al.

JCO PRECISION ONCOLOGY (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers

Conan G. Kinsey et al.

NATURE MEDICINE (2019)

添加到收藏夹

Article Medicine, Research & Experimental

Evaluation of worldwide clinical trials by gender: An FDA perspective

Emily Ayuso et al.

CONTEMPORARY CLINICAL TRIALS (2019)

添加到收藏夹

Article Pharmacology & Pharmacy

Gender differences in clinical registration trials: is there a real problem?

Geert Labots et al.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2018)

添加到收藏夹

Article Gastroenterology & Hepatology

Stratification of Pancreatic Ductal Adenocarcinomas Based on Tumor and Microenvironment Features

Francesco Puleo et al.

GASTROENTEROLOGY (2018)

添加到收藏夹

Review Oncology

Challenging Standard-of-Care Paradigms in the Precision Oncology Era

Vivek Subbiah et al.

TRENDS IN CANCER (2018)

添加到收藏夹

Article Oncology

Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab

A. M. Menzies et al.

ANNALS OF ONCOLOGY (2017)

添加到收藏夹

Article Multidisciplinary Sciences

Genomic analyses identify molecular subtypes of pancreatic cancer

Peter Bailey et al.

NATURE (2016)

添加到收藏夹

Article Multidisciplinary Sciences

Whole genomes redefine the mutational landscape of pancreatic cancer

Nicola Waddell et al.

NATURE (2015)

添加到收藏夹

Article Medicine, General & Internal

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

Daniel D. Von Hoff et al.

NEW ENGLAND JOURNAL OF MEDICINE (2013)

添加到收藏夹

Article Medicine, General & Internal

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

Thierry Conroy et al.

NEW ENGLAND JOURNAL OF MEDICINE (2011)

添加到收藏夹

Article Public, Environmental & Occupational Health

INCREASING PARTICIPATION OF WOMEN IN EARLY PHASE CLINICAL TRIALS APPROVED BY THE FDA

Ellen Pinnow et al.

WOMENS HEALTH ISSUES (2009)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.